首页 > 最新文献

Journal of Enzyme Inhibition and Medicinal Chemistry最新文献

英文 中文
Fluorinated indeno-quinoxaline bearing thiazole moieties as hypoglycaemic agents targeting α-amylase, and α-glucosidase: synthesis, molecular docking, and ADMET studies. 以α-淀粉酶和α-葡萄糖苷酶为靶标的含噻唑分子的氟化茚喹喔啉类降血糖药:合成、分子对接和 ADMET 研究。
IF 5.6 2区 医学 Q1 BIOCHEMISTRY & MOLECULAR BIOLOGY Pub Date : 2024-12-01 Epub Date: 2024-06-24 DOI: 10.1080/14756366.2024.2367128
Nirvana A Gohar, Eman A Fayed, Yousry A Ammar, Ola A Abu Ali, Ahmed Ragab, Amal M Mahfoz, Moustafa S Abusaif

Inhibition of α-glucosidase and α-amylase are key tactics for managing blood glucose levels. Currently, stronger, and more accessible inhibitors are needed to treat diabetes. Indeno[1,2-b] quinoxalines-carrying thiazole hybrids 1-17 were created and described using NMR. All analogues were tested for hypoglycaemic effect against STZ-induced diabetes in mice. Compounds 4, 6, 8, and 16 were the most potent among the synthesised analogues. These hybrids were examined for their effects on plasma insulin, urea, creatinine, GSH, MDA, ALT, AST, and total cholesterol. Moreover, these compounds were tested against α-glucosidase and α-amylase enzymes in vitro. The four hybrids 4, 6, 8, and 16 represented moderate to potent activity with IC50 values 0.982 ± 0.04, to 10.19 ± 0.21 for α-glucosidase inhibition and 17.58 ± 0.74 to 121.6 ± 5.14 μM for α-amylase inhibition when compared to the standard medication acarbose with IC50=0.316 ± 0.02 μM for α-glucosidase inhibition and 31.56 ± 1.33 μM for α-amylase inhibition. Docking studies as well as in silico ADMT were done.

抑制α-葡萄糖苷酶和α-淀粉酶是控制血糖水平的关键手段。目前,治疗糖尿病需要更强、更易获得的抑制剂。我们利用核磁共振技术创造并描述了茚并[1,2-b]喹喔啉-载噻唑杂交化合物 1-17。测试了所有类似物对 STZ 诱导的小鼠糖尿病的降血糖作用。在合成的类似物中,化合物 4、6、8 和 16 的效力最强。这些混合物对血浆胰岛素、尿素、肌酐、GSH、MDA、ALT、AST 和总胆固醇都有影响。此外,还对这些化合物进行了抗α-葡萄糖苷酶和α-淀粉酶的体外测试。4、6、8 和 16 四种杂交化合物具有中等至强效活性,对α-葡萄糖苷酶的抑制作用 IC50 值为 0.982 ± 0.04 至 10.19 ± 0.21,对α-淀粉酶的抑制作用 IC50 值为 17.58 ± 0.74 至 121.6 ± 5。14 μM,而标准药物阿卡波糖的α-葡萄糖苷酶抑制作用 IC50=0.316 ± 0.02 μM,α-淀粉酶抑制作用 IC50=31.56 ± 1.33 μM。研究人员进行了对接研究和硅学 ADMT 研究。
{"title":"Fluorinated indeno-quinoxaline bearing thiazole moieties as hypoglycaemic agents targeting <i>α</i>-amylase, and <i>α</i>-glucosidase: synthesis, molecular docking, and ADMET studies.","authors":"Nirvana A Gohar, Eman A Fayed, Yousry A Ammar, Ola A Abu Ali, Ahmed Ragab, Amal M Mahfoz, Moustafa S Abusaif","doi":"10.1080/14756366.2024.2367128","DOIUrl":"10.1080/14756366.2024.2367128","url":null,"abstract":"<p><p>Inhibition of α-glucosidase and <i>α</i>-amylase are key tactics for managing blood glucose levels. Currently, stronger, and more accessible inhibitors are needed to treat diabetes. Indeno[1,2-<i>b</i>] quinoxalines-carrying thiazole hybrids <b>1-17</b> were created and described using NMR. All analogues were tested for hypoglycaemic effect against STZ-induced diabetes in mice. Compounds <b>4</b>, <b>6</b>, <b>8</b>, and <b>16</b> were the most potent among the synthesised analogues. These hybrids were examined for their effects on plasma insulin, urea, creatinine, GSH, MDA, ALT, AST, and total cholesterol. Moreover, these compounds were tested against <i>α</i>-glucosidase and <i>α</i>-amylase enzymes <i>in vitro</i>. The four hybrids <b>4</b>, <b>6</b>, <b>8</b>, and <b>16</b> represented moderate to potent activity with IC<sub>50</sub> values 0.982 ± 0.04, to 10.19 ± 0.21 for <i>α</i>-glucosidase inhibition and 17.58 ± 0.74 to 121.6 ± 5.14 μM for <i>α</i>-amylase inhibition when compared to the standard medication acarbose with IC<sub>50</sub>=0.316 ± 0.02 μM for <i>α</i>-glucosidase inhibition and 31.56 ± 1.33 μM for <i>α</i>-amylase inhibition. Docking studies as well as <i>in silico</i> ADMT were done.</p>","PeriodicalId":15769,"journal":{"name":"Journal of Enzyme Inhibition and Medicinal Chemistry","volume":null,"pages":null},"PeriodicalIF":5.6,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC467095/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141446338","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
The repertoire of iron superoxide dismutases from Leishmania infantum as targets in the search for therapeutic agents against leishmaniasis. 将婴儿利什曼原虫的铁超氧化物歧化酶作为寻找利什曼病治疗药物的目标。
IF 5.6 2区 医学 Q1 BIOCHEMISTRY & MOLECULAR BIOLOGY Pub Date : 2024-12-01 Epub Date: 2024-07-22 DOI: 10.1080/14756366.2024.2377586
Juan Carlos García-Soriano, Héctor de Lucio, Daniel Elvira-Blázquez, Mercedes Alcón-Calderón, Natalia Sanz Del Olmo, Pedro A Sánchez-Murcia, Paula Ortega, Francisco Javier de la Mata, Antonio Jiménez-Ruiz

Species of Leishmania and Trypanosoma genera are the causative agents of relevant parasitic diseases. Survival inside their hosts requires the existence of a potent antioxidant enzymatic machinery. Four iron superoxide dismutases have been described in trypanosomatids (FeSODA, FeSODB1, FeSODB2, and FeSODC) that hold a potential as therapeutic targets. Nonetheless, very few studies have been developed that make use of the purified enzymes. Moreover, FeSODC remains uncharacterised in Leishmania. In this work, for the first time, we describe the purification and enzymatic activity of recombinant versions of the four Leishmania FeSOD isoforms and establish an improved strategy for developing inhibitors. We propose a novel parameter [(V*cyt. c - Vcyt. c)/Vcyt. c] which, in contrast to that used in the classical cytochrome c reduction assay, correlates linearly with enzyme concentration. As a proof of concept, we determine the IC50 values of two ruthenium carbosilane metallodendrimers against these isoforms.

利什曼原虫属和锥虫属是相关寄生虫病的病原体。要在宿主体内生存,就必须有强大的抗氧化酶机制。在锥虫中已描述了四种铁超氧化物歧化酶(FeSODA、FeSODB1、FeSODB2 和 FeSODC),它们有可能成为治疗目标。然而,利用这些纯化酶进行的研究还很少。此外,FeSODC 在利什曼原虫中仍未定性。在这项工作中,我们首次描述了重组的四种利什曼原虫 FeSOD 同工酶的纯化和酶活性,并建立了开发抑制剂的改进策略。我们提出了一个新的参数[(V*cyt. c - Vcyt. c)/Vcyt. c],与经典的细胞色素 c 还原测定中使用的参数不同,该参数与酶浓度呈线性相关。作为概念验证,我们确定了两种钌碳硅烷金属二聚体对这些异构体的 IC50 值。
{"title":"The repertoire of iron superoxide dismutases from <i>Leishmania infantum</i> as targets in the search for therapeutic agents against leishmaniasis.","authors":"Juan Carlos García-Soriano, Héctor de Lucio, Daniel Elvira-Blázquez, Mercedes Alcón-Calderón, Natalia Sanz Del Olmo, Pedro A Sánchez-Murcia, Paula Ortega, Francisco Javier de la Mata, Antonio Jiménez-Ruiz","doi":"10.1080/14756366.2024.2377586","DOIUrl":"https://doi.org/10.1080/14756366.2024.2377586","url":null,"abstract":"<p><p>Species of <i>Leishmania</i> and <i>Trypanosoma</i> genera are the causative agents of relevant parasitic diseases. Survival inside their hosts requires the existence of a potent antioxidant enzymatic machinery. Four iron superoxide dismutases have been described in trypanosomatids (FeSODA, FeSODB1, FeSODB2, and FeSODC) that hold a potential as therapeutic targets. Nonetheless, very few studies have been developed that make use of the purified enzymes. Moreover, FeSODC remains uncharacterised in <i>Leishmania</i>. In this work, for the first time, we describe the purification and enzymatic activity of recombinant versions of the four <i>Leishmania</i> FeSOD isoforms and establish an improved strategy for developing inhibitors. We propose a novel parameter [(<i>V</i>*<sub>cyt. c</sub> - <i>V</i><sub>cyt. c</sub>)/<i>V</i><sub>cyt. c</sub>] which, in contrast to that used in the classical cytochrome c reduction assay, correlates linearly with enzyme concentration. As a proof of concept, we determine the IC<sub>50</sub> values of two ruthenium carbosilane metallodendrimers against these isoforms.</p>","PeriodicalId":15769,"journal":{"name":"Journal of Enzyme Inhibition and Medicinal Chemistry","volume":null,"pages":null},"PeriodicalIF":5.6,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141734333","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Watermelon: setup and validation of an in silico fragment-based approach. 西瓜:基于片段的硅学方法的设置和验证。
IF 5.6 2区 医学 Q1 BIOCHEMISTRY & MOLECULAR BIOLOGY Pub Date : 2024-12-01 Epub Date: 2024-06-12 DOI: 10.1080/14756366.2024.2356179
Miriana Di Stefano, Salvatore Galati, Lisa Piazza, Francesca Gado, Carlotta Granchi, Marco Macchia, Antonio Giordano, Tiziano Tuccinardi, Giulio Poli

We present a new computational approach, named Watermelon, designed for the development of pharmacophore models based on receptor structures. The methodology involves the sampling of potential hotspots for ligand interactions within a protein target's binding site, utilising molecular fragments as probes. By employing docking and molecular dynamics (MD) simulations, the most significant interactions formed by these probes within distinct regions of the binding site are identified. These interactions are subsequently transformed into pharmacophore features that delineates key anchoring sites for potential ligands. The reliability of the approach was experimentally validated using the monoacylglycerol lipase (MAGL) enzyme. The generated pharmacophore model captured features representing ligand-MAGL interactions observed in various X-ray co-crystal structures and was employed to screen a database of commercially available compounds, in combination with consensus docking and MD simulations. The screening successfully identified two new MAGL inhibitors with micromolar potency, thus confirming the reliability of the Watermelon approach.

我们介绍了一种名为 "西瓜"(Watermelon)的新计算方法,该方法专为开发基于受体结构的药效模型而设计。该方法利用分子片段作为探针,对蛋白质靶点结合位点内配体相互作用的潜在热点进行采样。通过采用对接和分子动力学(MD)模拟,确定这些探针在结合位点不同区域内形成的最重要的相互作用。这些相互作用随后被转化为药理特征,为潜在配体划定关键锚定位点。该方法的可靠性通过单酰基甘油脂肪酶(MAGL)酶进行了实验验证。生成的药理模型捕捉了在各种 X 射线共晶体结构中观察到的配体-MAGL 相互作用特征,并结合共识对接和 MD 模拟,用于筛选市售化合物数据库。这次筛选成功鉴定了两种具有微摩尔效力的新型 MAGL 抑制剂,从而证实了西瓜方法的可靠性。
{"title":"Watermelon: setup and validation of an <i>in silico</i> fragment-based approach.","authors":"Miriana Di Stefano, Salvatore Galati, Lisa Piazza, Francesca Gado, Carlotta Granchi, Marco Macchia, Antonio Giordano, Tiziano Tuccinardi, Giulio Poli","doi":"10.1080/14756366.2024.2356179","DOIUrl":"10.1080/14756366.2024.2356179","url":null,"abstract":"<p><p>We present a new computational approach, named <i>Watermelon</i>, designed for the development of pharmacophore models based on receptor structures. The methodology involves the sampling of potential hotspots for ligand interactions within a protein target's binding site, utilising molecular fragments as probes. By employing docking and molecular dynamics (MD) simulations, the most significant interactions formed by these probes within distinct regions of the binding site are identified. These interactions are subsequently transformed into pharmacophore features that delineates key anchoring sites for potential ligands. The reliability of the approach was experimentally validated using the monoacylglycerol lipase (MAGL) enzyme. The generated pharmacophore model captured features representing ligand-MAGL interactions observed in various X-ray co-crystal structures and was employed to screen a database of commercially available compounds, in combination with consensus docking and MD simulations. The screening successfully identified two new MAGL inhibitors with micromolar potency, thus confirming the reliability of the <i>Watermelon</i> approach.</p>","PeriodicalId":15769,"journal":{"name":"Journal of Enzyme Inhibition and Medicinal Chemistry","volume":null,"pages":null},"PeriodicalIF":5.6,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11232643/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141306106","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Development of certain benzylidene coumarin derivatives as anti-prostate cancer agents targeting EGFR and PI3Kβ kinases. 将某些苯亚甲基香豆素衍生物开发为靶向表皮生长因子受体(EGFR)和 PI3Kβ 激酶的抗前列腺癌药物。
IF 5.6 2区 医学 Q1 Pharmacology, Toxicology and Pharmaceutics Pub Date : 2024-12-01 Epub Date: 2024-02-13 DOI: 10.1080/14756366.2024.2311157
Mohamed Elagawany, Lina M A Abdel Ghany, Tarek S Ibrahim, Abdulrhman S Alharbi, Mohamed S Abdel-Aziz, Eman M El-Labbad, Noha Ryad

Novel coumarin derivatives were synthesised and tested for their cytotoxicity against human cancer cells (PC-3 and MDA-MB-231). Compounds 5, 4b, and 4a possessed potent cytotoxic activity against PC-3 cells with IC50 3.56, 8.99, and 10.22 µM, respectively. Compound 4c displayed cytotoxicity more than erlotinib in the MDA-MB-231 cells with IC50 8.5 µM. Moreover, compound 5 exhibited potent inhibitory activity on EFGR with IC50 0.1812 µM, as well as PI3Kβ inhibitory activity that was twofold higher than LY294002, suggesting that this compound has a dual EGFR and PI3Kβ inhibiting activity. Docking aligns with the in vitro results and sheds light on the molecular mechanisms underlying dual targeting. Furthermore, compound 5 decreased AKT and m-TOR expression in PC-3 cells, showing that it specifically targets these cells via the EGFR/PI3K/Akt/m-TOR signalling pathway. Simultaneously, compound 5 caused cell cycle arrest at S phase and induced activation of both intrinsic and extrinsic apoptotic pathways.

合成了新型香豆素衍生物,并测试了它们对人类癌细胞(PC-3 和 MDA-MB-231)的细胞毒性。化合物 5、4b 和 4a 对 PC-3 细胞具有很强的细胞毒性,IC50 分别为 3.56、8.99 和 10.22 µM。化合物 4c 对 MDA-MB-231 细胞的细胞毒性高于厄洛替尼,IC50 为 8.5 µM。此外,化合物 5 对 EFGR 具有强效抑制活性,IC50 为 0.1812 µM,对 PI3Kβ 的抑制活性是 LY294002 的两倍,表明该化合物具有 EGFR 和 PI3Kβ 双重抑制活性。对接结果与体外结果一致,揭示了双重靶向的分子机制。此外,化合物 5 还能降低 PC-3 细胞中 AKT 和 m-TOR 的表达,表明它能通过表皮生长因子受体/PI3K/Akt/m-TOR 信号通路特异性地靶向这些细胞。同时,化合物 5 还能使细胞周期停滞在 S 期,并诱导激活细胞内在和外在凋亡途径。
{"title":"Development of certain benzylidene coumarin derivatives as anti-prostate cancer agents targeting EGFR and PI3Kβ kinases.","authors":"Mohamed Elagawany, Lina M A Abdel Ghany, Tarek S Ibrahim, Abdulrhman S Alharbi, Mohamed S Abdel-Aziz, Eman M El-Labbad, Noha Ryad","doi":"10.1080/14756366.2024.2311157","DOIUrl":"10.1080/14756366.2024.2311157","url":null,"abstract":"<p><p>Novel coumarin derivatives were synthesised and tested for their cytotoxicity against human cancer cells (PC-3 and MDA-MB-231). Compounds <b>5</b>, <b>4b</b>, and <b>4a</b> possessed potent cytotoxic activity against PC-3 cells with IC<sub>50</sub> 3.56, 8.99, and 10.22 µM, respectively. Compound <b>4c</b> displayed cytotoxicity more than erlotinib in the MDA-MB-231 cells with IC<sub>50</sub> 8.5 µM. Moreover, compound <b>5</b> exhibited potent inhibitory activity on EFGR with IC<sub>50</sub> 0.1812 µM, as well as PI3Kβ inhibitory activity that was twofold higher than LY294002, suggesting that this compound has a dual EGFR and PI3Kβ inhibiting activity. Docking aligns with the <i>in vitro</i> results and sheds light on the molecular mechanisms underlying dual targeting. Furthermore, compound <b>5</b> decreased AKT and m-TOR expression in PC-3 cells, showing that it specifically targets these cells via the EGFR/PI3K/Akt/m-TOR signalling pathway. Simultaneously, compound <b>5</b> caused cell cycle arrest at S phase and induced activation of both intrinsic and extrinsic apoptotic pathways.</p>","PeriodicalId":15769,"journal":{"name":"Journal of Enzyme Inhibition and Medicinal Chemistry","volume":null,"pages":null},"PeriodicalIF":5.6,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10866054/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139722893","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Discovery of novel and potent dual-targeting AXL/HDAC2 inhibitors for colorectal cancer treatment via structure-based pharmacophore modelling, virtual screening, and molecular docking, molecular dynamics simulation studies, and biological evaluation. 通过基于结构的药效学建模、虚拟筛选、分子对接、分子动力学模拟研究和生物学评价,发现治疗结直肠癌的新型强效 AXL/HDAC2 双靶向抑制剂。
IF 5.6 2区 医学 Q1 Pharmacology, Toxicology and Pharmaceutics Pub Date : 2024-12-01 Epub Date: 2023-12-22 DOI: 10.1080/14756366.2023.2295241
Xiao Qiao, Xiangyu Wu, Shutong Chen, Miao-Miao Niu, Huilian Hua, Yan Zhang

Colorectal cancer (CRC) is one of the most common cancers worldwide. Nowadays, owing to the complex mechanism of tumorigenesis, simultaneous inhibition of multiple targets is an important anticancer strategy. Recent studies have demonstrated receptor tyrosine kinase AXL (AXL) and histone deacetylase 2 (HDAC2) are closely associated with colorectal cancer. Herein, we identified five hit compounds concurrently targeting AXL and HDAC2 using virtual screening. Inhibitory experiments revealed these hit compounds potently inhibited AXL and HDAC2 in the nanomolar range. Among them, Hit-3 showed the strongest inhibitory effects which were better than that of the positive control groups. Additionally, MD assays showed that Hit-3 could bind stably to the AXL and HDAC2 active pockets. Further MTT assays demonstrated that Hit-3 showed potent anti-proliferative activity. Most importantly, Hit-3 exhibited significant in vivo antitumor efficacy in xenograft models. Collectively, this study is the first discovery of dual-targeting AXL/HDAC2 inhibitors for colorectal cancer treatment.

结直肠癌(CRC)是全球最常见的癌症之一。目前,由于肿瘤发生机制复杂,同时抑制多个靶点是一种重要的抗癌策略。最近的研究表明,受体酪氨酸激酶AXL(AXL)和组蛋白去乙酰化酶2(HDAC2)与结直肠癌密切相关。在此,我们通过虚拟筛选确定了五种同时靶向 AXL 和 HDAC2 的热门化合物。抑制实验显示,这些命中化合物在纳摩尔范围内对AXL和HDAC2具有强效抑制作用。其中,Hit-3的抑制效果最强,优于阳性对照组。此外,MD 试验表明,Hit-3 能与 AXL 和 HDAC2 的活性口袋稳定结合。进一步的 MTT 试验表明,Hit-3 具有很强的抗增殖活性。最重要的是,Hit-3 在异种移植模型中表现出显著的体内抗肿瘤疗效。总之,这项研究首次发现了用于结直肠癌治疗的 AXL/HDAC2 双靶向抑制剂。
{"title":"Discovery of novel and potent dual-targeting AXL/HDAC2 inhibitors for colorectal cancer treatment via structure-based pharmacophore modelling, virtual screening, and molecular docking, molecular dynamics simulation studies, and biological evaluation.","authors":"Xiao Qiao, Xiangyu Wu, Shutong Chen, Miao-Miao Niu, Huilian Hua, Yan Zhang","doi":"10.1080/14756366.2023.2295241","DOIUrl":"10.1080/14756366.2023.2295241","url":null,"abstract":"<p><p>Colorectal cancer (CRC) is one of the most common cancers worldwide. Nowadays, owing to the complex mechanism of tumorigenesis, simultaneous inhibition of multiple targets is an important anticancer strategy. Recent studies have demonstrated receptor tyrosine kinase AXL (AXL) and histone deacetylase 2 (HDAC2) are closely associated with colorectal cancer. Herein, we identified five hit compounds concurrently targeting AXL and HDAC2 using virtual screening. Inhibitory experiments revealed these hit compounds potently inhibited AXL and HDAC2 in the nanomolar range. Among them, Hit-3 showed the strongest inhibitory effects which were better than that of the positive control groups. Additionally, MD assays showed that Hit-3 could bind stably to the AXL and HDAC2 active pockets. Further MTT assays demonstrated that Hit-3 showed potent anti-proliferative activity. Most importantly, Hit-3 exhibited significant <i>in vivo</i> antitumor efficacy in xenograft models. Collectively, this study is the first discovery of dual-targeting AXL/HDAC2 inhibitors for colorectal cancer treatment.</p>","PeriodicalId":15769,"journal":{"name":"Journal of Enzyme Inhibition and Medicinal Chemistry","volume":null,"pages":null},"PeriodicalIF":5.6,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10763849/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"138885025","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
o-Vanillin binds covalently to MAL/TIRAP Lys-210 but independently inhibits TLR2. o-香兰素与 MAL/TIRAP Lys-210 共价结合,但独立抑制 TLR2。
IF 5.6 2区 医学 Q1 Pharmacology, Toxicology and Pharmaceutics Pub Date : 2024-12-01 Epub Date: 2024-02-28 DOI: 10.1080/14756366.2024.2313055
Md Habibur Rahaman, Sara J Thygesen, Michael J Maxwell, Hyoyoung Kim, Prerna Mudai, Jeffrey D Nanson, Xinying Jia, Parimala R Vajjhala, Andrew Hedger, Irina Vetter, Thomas Haselhorst, Avril A B Robertson, Brian Dymock, Thomas Ve, Mehdi Mobli, Katryn J Stacey, Bostjan Kobe

Toll-like receptor (TLR) innate immunity signalling protects against pathogens, but excessive or prolonged signalling contributes to a range of inflammatory conditions. Structural information on the TLR cytoplasmic TIR (Toll/interleukin-1 receptor) domains and the downstream adaptor proteins can help us develop inhibitors targeting this pathway. The small molecule o-vanillin has previously been reported as an inhibitor of TLR2 signalling. To study its mechanism of action, we tested its binding to the TIR domain of the TLR adaptor MAL/TIRAP (MALTIR). We show that o-vanillin binds to MALTIR and inhibits its higher-order assembly in vitro. Using NMR approaches, we show that o-vanillin forms a covalent bond with lysine 210 of MAL. We confirm in mouse and human cells that o-vanillin inhibits TLR2 but not TLR4 signalling, independently of MAL, suggesting it may covalently modify TLR2 signalling complexes directly. Reactive aldehyde-containing small molecules such as o-vanillin may target multiple proteins in the cell.

Toll 样受体(Toll-like receptor,TLR)先天性免疫信号可保护人体免受病原体的侵害,但过度或长时间的信号传导会导致一系列炎症。有关 TLR 细胞质 TIR(Toll/白细胞介素-1 受体)结构域和下游适配蛋白的结构信息有助于我们开发针对这一途径的抑制剂。据报道,小分子邻香兰素是 TLR2 信号的抑制剂。为了研究其作用机制,我们测试了它与 TLR 适配蛋白 MAL/TIRAP (MALTIR)的 TIR 结构域的结合情况。我们发现邻香兰素能与 MALTIR 结合,并在体外抑制其高阶组装。通过核磁共振方法,我们发现邻香兰素与 MAL 的赖氨酸 210 形成了共价键。我们在小鼠和人体细胞中证实,邻香兰素能抑制 TLR2 信号,但不能抑制 TLR4 信号,这与 MAL 无关,表明邻香兰素可能直接共价修饰 TLR2 信号复合物。邻香兰素等含反应醛的小分子可能以细胞中的多种蛋白质为靶标。
{"title":"o-Vanillin binds covalently to MAL/TIRAP Lys-210 but independently inhibits TLR2.","authors":"Md Habibur Rahaman, Sara J Thygesen, Michael J Maxwell, Hyoyoung Kim, Prerna Mudai, Jeffrey D Nanson, Xinying Jia, Parimala R Vajjhala, Andrew Hedger, Irina Vetter, Thomas Haselhorst, Avril A B Robertson, Brian Dymock, Thomas Ve, Mehdi Mobli, Katryn J Stacey, Bostjan Kobe","doi":"10.1080/14756366.2024.2313055","DOIUrl":"10.1080/14756366.2024.2313055","url":null,"abstract":"<p><p>Toll-like receptor (TLR) innate immunity signalling protects against pathogens, but excessive or prolonged signalling contributes to a range of inflammatory conditions. Structural information on the TLR cytoplasmic TIR (Toll/interleukin-1 receptor) domains and the downstream adaptor proteins can help us develop inhibitors targeting this pathway. The small molecule o-vanillin has previously been reported as an inhibitor of TLR2 signalling. To study its mechanism of action, we tested its binding to the TIR domain of the TLR adaptor MAL/TIRAP (MAL<sup>TIR</sup>). We show that o-vanillin binds to MAL<sup>TIR</sup> and inhibits its higher-order assembly <i>in vitro</i>. Using NMR approaches, we show that o-vanillin forms a covalent bond with lysine 210 of MAL. We confirm in mouse and human cells that o-vanillin inhibits TLR2 but not TLR4 signalling, independently of MAL, suggesting it may covalently modify TLR2 signalling complexes directly. Reactive aldehyde-containing small molecules such as o-vanillin may target multiple proteins in the cell.</p>","PeriodicalId":15769,"journal":{"name":"Journal of Enzyme Inhibition and Medicinal Chemistry","volume":null,"pages":null},"PeriodicalIF":5.6,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10903754/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139990277","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Druggable cavities and allosteric modulators of the cell division cycle 7 (CDC7) kinase. 细胞分裂周期 7 (CDC7) 激酶的药腔和异位调节剂。
IF 5.6 2区 医学 Q1 Pharmacology, Toxicology and Pharmaceutics Pub Date : 2024-12-01 Epub Date: 2024-01-11 DOI: 10.1080/14756366.2024.2301767
Elisa Rojas-Prats, Loreto Martinez-Gonzalez, Carmen Gil, David Ramírez, Ana Martinez

Cell division cycle 7 kinase (CDC7) has been found overexpressed in many cancer cell lines being also one of the kinases involved in the nuclear protein TDP-43 phosphorylation in vivo. Thus, inhibitors of CDC7 are emerging drug candidates for the treatment of oncological and neurodegenerative unmet diseases. All the known CDC7 inhibitors are ATP-competitives, lacking of selectivity enough for success in clinical trials. As allosteric sites are less conserved among kinase proteins, discovery of allosteric modulators of CDC7 is a great challenge and opportunity in this field.Using different computational approaches, we have here identified new druggable cavities on the human CDC7 structure and subsequently selective CDC7 inhibitors with allosteric modulation mainly targeting the pockets where the interaction between this kinase and its activator DBF4 takes place.

细胞分裂周期 7 激酶(CDC7)被发现在许多癌细胞系中过度表达,也是参与体内核蛋白 TDP-43 磷酸化的激酶之一。因此,CDC7 抑制剂是治疗肿瘤和神经退行性疾病的新兴候选药物。所有已知的 CDC7 抑制剂都是 ATP 竞争性的,缺乏足够的选择性,因此无法在临床试验中取得成功。利用不同的计算方法,我们在人类 CDC7 结构上发现了新的可药用空腔,并随后发现了具有选择性的 CDC7 抑制剂,这些抑制剂主要针对该激酶与其激活剂 DBF4 之间发生相互作用的空腔进行异构调节。
{"title":"Druggable cavities and allosteric modulators of the cell division cycle 7 (CDC7) kinase.","authors":"Elisa Rojas-Prats, Loreto Martinez-Gonzalez, Carmen Gil, David Ramírez, Ana Martinez","doi":"10.1080/14756366.2024.2301767","DOIUrl":"10.1080/14756366.2024.2301767","url":null,"abstract":"<p><p>Cell division cycle 7 kinase (CDC7) has been found overexpressed in many cancer cell lines being also one of the kinases involved in the nuclear protein TDP-43 phosphorylation <i>in vivo</i>. Thus, inhibitors of CDC7 are emerging drug candidates for the treatment of oncological and neurodegenerative unmet diseases. All the known CDC7 inhibitors are ATP-competitives, lacking of selectivity enough for success in clinical trials. As allosteric sites are less conserved among kinase proteins, discovery of allosteric modulators of CDC7 is a great challenge and opportunity in this field.Using different computational approaches, we have here identified new druggable cavities on the human CDC7 structure and subsequently selective CDC7 inhibitors with allosteric modulation mainly targeting the pockets where the interaction between this kinase and its activator DBF4 takes place.</p>","PeriodicalId":15769,"journal":{"name":"Journal of Enzyme Inhibition and Medicinal Chemistry","volume":null,"pages":null},"PeriodicalIF":5.6,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10786434/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139417218","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Design, synthesis, and evaluation of novel stilbene derivatives that degrade acidic nucleoplasmic DNA-binding protein 1 (And1) and synergize with PARP1 inhibitor in NSCLC cells. 设计、合成和评估能降解酸性核质 DNA 结合蛋白 1 (And1) 并与 PARP1 抑制剂协同作用于 NSCLC 细胞的新型二苯乙烯衍生物。
IF 5.6 2区 医学 Q1 BIOCHEMISTRY & MOLECULAR BIOLOGY Pub Date : 2024-12-01 Epub Date: 2024-07-29 DOI: 10.1080/14756366.2024.2383886
Leyuan Chen, Zhonghao Ren, Yunze Zhang, Wenbin Hou, Yiliang Li

Specifically inducing the degradation of acidic nucleoplasmic DNA-binding protein 1 (And1) is a promising antitumor strategy. Our previous study identified Bazedoxifene (BZA) and CH3 as specific And1 degraders and validated their activity in reversing radiotherapy resistance in vitro and in vivo. However, unelucidated structure-activity relationships and moderate activity have limited their application. In this study, 27 novel CH3 derivatives were designed and synthesised based on the cavity topology of the WD40 domain of And1. Among them, A15 with a "V" conformation significantly induced And1 degradation in NSCLC cells. In addition, this study demonstrated a potential synthetic lethal effect of And1 degraders and PARP1 inhibitors. 1 µM of Olaparib in combination with 5 µM of A15 significantly inhibited the proliferation of A549 and H460 cells. Overall, these compounds are valuable tools for elucidating And1 biology, and their special spatial conformation make them promising candidates for future optimisation studies.

专门诱导酸性核质DNA结合蛋白1(And1)降解是一种很有前景的抗肿瘤策略。我们之前的研究发现,Bazedoxifene(BZA)和CH3是特异性的And1降解剂,并验证了它们在体外和体内逆转放疗耐药性的活性。然而,结构-活性关系的不明确和适度的活性限制了它们的应用。本研究根据 And1 WD40 结构域的空腔拓扑结构设计并合成了 27 种新型 CH3 衍生物。其中,具有 "V "构象的 A15 能显著诱导 NSCLC 细胞中 And1 的降解。此外,这项研究还证明了And1降解剂和PARP1抑制剂的潜在合成致死效应。1 µM 的 Olaparib 与 5 µM 的 A15 联用可明显抑制 A549 和 H460 细胞的增殖。总之,这些化合物是阐明 And1 生物学特性的宝贵工具,其特殊的空间构象使它们有望成为未来优化研究的候选化合物。
{"title":"Design, synthesis, and evaluation of novel stilbene derivatives that degrade acidic nucleoplasmic DNA-binding protein 1 (And1) and synergize with PARP1 inhibitor in NSCLC cells.","authors":"Leyuan Chen, Zhonghao Ren, Yunze Zhang, Wenbin Hou, Yiliang Li","doi":"10.1080/14756366.2024.2383886","DOIUrl":"10.1080/14756366.2024.2383886","url":null,"abstract":"<p><p>Specifically inducing the degradation of acidic nucleoplasmic DNA-binding protein 1 (And1) is a promising antitumor strategy. Our previous study identified Bazedoxifene (BZA) and CH3 as specific And1 degraders and validated their activity in reversing radiotherapy resistance <i>in vitro</i> and <i>in vivo</i>. However, unelucidated structure-activity relationships and moderate activity have limited their application. In this study, 27 novel CH3 derivatives were designed and synthesised based on the cavity topology of the WD40 domain of And1. Among them, <b>A15</b> with a \"V\" conformation significantly induced And1 degradation in NSCLC cells. In addition, this study demonstrated a potential synthetic lethal effect of And1 degraders and PARP1 inhibitors. 1 µM of Olaparib in combination with 5 µM of <b>A15</b> significantly inhibited the proliferation of A549 and H460 cells. Overall, these compounds are valuable tools for elucidating And1 biology, and their special spatial conformation make them promising candidates for future optimisation studies.</p>","PeriodicalId":15769,"journal":{"name":"Journal of Enzyme Inhibition and Medicinal Chemistry","volume":null,"pages":null},"PeriodicalIF":5.6,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11288208/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141788224","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Design, synthesis, in vitro and in vivo biological evaluation of pterostilbene derivatives for anti-inflammation therapy. 用于抗炎治疗的紫檀芪衍生物的设计、合成、体外和体内生物学评价。
IF 5.6 2区 医学 Q1 Pharmacology, Toxicology and Pharmaceutics Pub Date : 2024-12-01 Epub Date: 2024-02-29 DOI: 10.1080/14756366.2024.2315227
Liuzeng Chen, Ke Wang, Xiaohan Liu, Lifan Wang, Hui Zou, Shuying Hu, Lingling Zhou, Rong Li, Shiying Cao, Banfeng Ruan, Quanren Cui

Pterostilbene (PST) is a naturally derived stilbene compound in grapes, blueberries, and other fruits. It is also a natural dietary compound with a wide range of biological activities such as antioxidant, anti-inflammatory, antitumor, and so on. Structural modifications based on the chemical scaffold of the pterostilbene skeleton are of great importance for drug discovery. In this study, pterostilbene skeletons were used to design novel anti-inflammatory compounds with high activity and low toxicity. A total of 30 new were found and synthesised, and their anti-inflammatory activity and safety were screened. Among them, compound E2 was the most active (against NO: IC50 = 0.7 μM) than celecoxib. Further studies showed that compound E2 exerted anti-inflammatory activity by blocking LPS-induced NF-κB/MAPK signalling pathway activation. In vivo experiments revealed that compound E2 had a good alleviating effect on acute colitis in mice. In conclusion, compound E2 may be a promising anti-inflammatory lead compound.

紫檀芪(PST)是葡萄、蓝莓和其他水果中天然提取的一种链烯化合物。它也是一种天然膳食化合物,具有抗氧化、抗炎、抗肿瘤等多种生物活性。基于紫檀芪骨架的化学支架进行结构改造对药物发现具有重要意义。本研究利用紫檀骨架设计了高活性、低毒性的新型抗炎化合物。共发现并合成了 30 个新化合物,并对其抗炎活性和安全性进行了筛选。其中,化合物 E2 比塞来昔布的活性最高(对 NO 的 IC50 = 0.7 μM)。进一步的研究表明,化合物 E2 通过阻断 LPS 诱导的 NF-κB/MAPK 信号通路活化而发挥抗炎活性。体内实验显示,化合物 E2 对小鼠急性结肠炎有良好的缓解作用。总之,化合物 E2 可能是一种很有前景的抗炎先导化合物。
{"title":"Design, synthesis, <i>in vitro</i> and <i>in vivo</i> biological evaluation of pterostilbene derivatives for anti-inflammation therapy.","authors":"Liuzeng Chen, Ke Wang, Xiaohan Liu, Lifan Wang, Hui Zou, Shuying Hu, Lingling Zhou, Rong Li, Shiying Cao, Banfeng Ruan, Quanren Cui","doi":"10.1080/14756366.2024.2315227","DOIUrl":"10.1080/14756366.2024.2315227","url":null,"abstract":"<p><p>Pterostilbene (PST) is a naturally derived stilbene compound in grapes, blueberries, and other fruits. It is also a natural dietary compound with a wide range of biological activities such as antioxidant, anti-inflammatory, antitumor, and so on. Structural modifications based on the chemical scaffold of the pterostilbene skeleton are of great importance for drug discovery. In this study, pterostilbene skeletons were used to design novel anti-inflammatory compounds with high activity and low toxicity. A total of 30 new were found and synthesised, and their anti-inflammatory activity and safety were screened. Among them, compound <b>E2</b> was the most active (against NO: IC<sub>50</sub> = 0.7 μM) than celecoxib. Further studies showed that compound <b>E2</b> exerted anti-inflammatory activity by blocking LPS-induced NF-κB/MAPK signalling pathway activation. <i>In vivo</i> experiments revealed that compound <b>E2</b> had a good alleviating effect on acute colitis in mice. In conclusion, compound <b>E2</b> may be a promising anti-inflammatory lead compound.</p>","PeriodicalId":15769,"journal":{"name":"Journal of Enzyme Inhibition and Medicinal Chemistry","volume":null,"pages":null},"PeriodicalIF":5.6,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10906133/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139990276","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Click estradiol dimers with novel aromatic bridging units: synthesis and anticancer evaluation. 具有新型芳香族桥接单元的点击雌二醇二聚体:合成与抗癌评估。
IF 5.6 2区 医学 Q1 BIOCHEMISTRY & MOLECULAR BIOLOGY Pub Date : 2024-12-01 Epub Date: 2024-06-21 DOI: 10.1080/14756366.2024.2367139
Jiří Řehulka, Michal Jurášek, Pavel Dráber, Aleksandra Ivanová, Soňa Gurská, Kateřina Ječmeňová, Olena Mokshyna, Marián Hajdúch, Pavel Polishchuk, Pavel B Drašar, Petr Džubák

Estradiol dimers (EDs) possess significant anticancer activity by targeting tubulin dynamics. In this study, we synthesised 12 EDs variants via copper-catalysed azide-alkyne cycloaddition (CuAAC) reaction, focusing on structural modifications within the aromatic bridge connecting two estradiol moieties. In vitro testing of these EDs revealed a marked improvement in selectivity towards cancerous cells, particularly for ED1-8. The most active compounds, ED3 (IC50 = 0.38 μM in CCRF-CEM) and ED5 (IC50 = 0.71 μM in CCRF-CEM) demonstrated cytotoxic effects superior to 2-methoxyestradiol (IC50 = 1.61 μM in CCRF-CEM) and exhibited anti-angiogenic properties in an endothelial cell tube-formation model. Cell-based experiments and in vitro assays revealed that EDs interfere with mitotic spindle assembly. Additionally, we proposed an in silico model illustrating the probable binding modes of ED3 and ED5, suggesting that dimers with a simple linker and a single substituent on the aromatic central ring possess enhanced characteristics compared to more complex dimers.

雌二醇二聚体(EDs)通过靶向微管蛋白动力学具有显著的抗癌活性。在这项研究中,我们通过铜催化叠氮-炔烃环加成(CuAAC)反应合成了 12 种 EDs 变体,重点研究了连接两个雌二醇分子的芳香桥的结构修饰。对这些 ED 的体外测试表明,它们对癌细胞的选择性明显提高,尤其是 ED1-8。最活跃的化合物 ED3(在 CCRF-CEM 中的 IC50 = 0.38 μM)和 ED5(在 CCRF-CEM 中的 IC50 = 0.71 μM)的细胞毒性效果优于 2-甲氧基雌二醇(在 CCRF-CEM 中的 IC50 = 1.61 μM),并在内皮细胞管形成模型中表现出抗血管生成特性。基于细胞的实验和体外试验显示,EDs 会干扰有丝分裂纺锤体的组装。此外,我们还提出了一个硅学模型,说明了 ED3 和 ED5 的可能结合模式,表明与更复杂的二聚体相比,具有简单连接体和芳香中心环上单一取代基的二聚体具有更强的特性。
{"title":"Click estradiol dimers with novel aromatic bridging units: synthesis and anticancer evaluation.","authors":"Jiří Řehulka, Michal Jurášek, Pavel Dráber, Aleksandra Ivanová, Soňa Gurská, Kateřina Ječmeňová, Olena Mokshyna, Marián Hajdúch, Pavel Polishchuk, Pavel B Drašar, Petr Džubák","doi":"10.1080/14756366.2024.2367139","DOIUrl":"10.1080/14756366.2024.2367139","url":null,"abstract":"<p><p>Estradiol dimers (EDs) possess significant anticancer activity by targeting tubulin dynamics. In this study, we synthesised 12 EDs variants via copper-catalysed azide-alkyne cycloaddition (CuAAC) reaction, focusing on structural modifications within the aromatic bridge connecting two estradiol moieties. <i>In vitro</i> testing of these EDs revealed a marked improvement in selectivity towards cancerous cells, particularly for ED1-8. The most active compounds, ED3 (IC<sub>50</sub> = 0.38 μM in CCRF-CEM) and ED5 (IC<sub>50</sub> = 0.71 μM in CCRF-CEM) demonstrated cytotoxic effects superior to 2-methoxyestradiol (IC<sub>50</sub> = 1.61 μM in CCRF-CEM) and exhibited anti-angiogenic properties in an endothelial cell tube-formation model. Cell-based experiments and <i>in vitro</i> assays revealed that EDs interfere with mitotic spindle assembly. Additionally, we proposed an <i>in silico</i> model illustrating the probable binding modes of ED3 and ED5, suggesting that dimers with a simple linker and a single substituent on the aromatic central ring possess enhanced characteristics compared to more complex dimers.</p>","PeriodicalId":15769,"journal":{"name":"Journal of Enzyme Inhibition and Medicinal Chemistry","volume":null,"pages":null},"PeriodicalIF":5.6,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC467089/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141432071","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
期刊
Journal of Enzyme Inhibition and Medicinal Chemistry
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1